NasdaqGM:OCULPharmaceuticals
Sanofi Rumored Bid And Regulatory Shifts Reframe Ocular Therapeutix Valuation
Rumors are circulating that Sanofi is considering a significantly higher acquisition bid for Ocular Therapeutix (NasdaqGM:OCUL).
The speculation follows recent regulatory developments that may create new or faster FDA approval routes for the company’s ophthalmology programs.
Market attention has increased as investors assess what a larger potential offer and altered commercialization timelines could mean for OCUL’s valuation and future role in eye care.
Ocular Therapeutix focuses on...